Dacomitinib but not lapatinib suppressed progression in castrationresistant prostate cancer models by preventing HER2 increase

Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase

22:48 EDT 17 Jun 2019 | Nature Publishing

More From BioPortfolio on "Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase"